Kazia Therapeutics
KZIA
5 hedge funds and large institutions have $269K invested in Kazia Therapeutics in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and 1 closing their positions.
15% more capital invested
Capital invested by funds: $233K → $269K (+$36K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.08M |
| 2 |
Morgan Stanley
New York
|
+$19.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$591 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $146K | +$19.2K | +130 | +16% |
|
2
Renaissance Technologies
New York
| $109K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $10K | +$2.96K | +20 | +49% |
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | – | – | – |
|
|
5
Bank of America
Charlotte,
North Carolina
| – | -$591 | -4 | Closed |
|
|
SM
6
Sabby Management
Miami Beach,
Florida
| – | +$1.08M | +7,333 | New |
|
KZIA Hedge Fund Activity: Q4 2017 in Review
5 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q4 2017, worth a combined $269K — up 15% from $233K a quarter earlier.
Fund positioning in KZIA was balanced in Q4 2017: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.08M. The largest seller was Bank of America, exiting entirely with an estimated $591 sold.
- 5 institutional investors held Kazia Therapeutics (KZIA) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $269K of Kazia Therapeutics stock for Q4 2017, up 15% quarter-over-quarter.
- 1 fund opened new Kazia Therapeutics positions in Q4 2017 and 1 closed out, a net change of 0 holders.
- The largest Kazia Therapeutics buyer in Q4 2017 was Sabby Management, an estimated $1.08M added.
- The largest Kazia Therapeutics seller in Q4 2017 was Bank of America, an estimated $591 sold.
Based on aggregated 13F filings for Q4 2017.